Ticagrelor

CHEMBL398435 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

522.6 g/mol

LogP

2.0

Phase

4

This antiplatelet medication is used to prevent blood clots in people who have had a heart attack or unstable angina, reducing the risk of future heart attacks and strokes. It works by blocking a receptor on platelets called P2Y12, making platelets less likely to clump together. It is typically taken along with low-dose aspirin and should not be stopped without consulting a doctor.

Peso Molecular

522,6000 g/mol

LogP

2,00

TPSA

164,00 Å²

Regra dos 5 de Lipinski

Reprovado

Áreas Terapêuticas

Cardiovascular Disease Rheumatoid Arthritis Chronic Obstructive Pulmonary Disease Migraine Insomnia Systemic Lupus Erythematosus Chronic Kidney Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Type 2 Diabetes Gout Heart Failure Atrial Fibrillation

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1

InChI

InChI=1S/C23H28F2N6O4S/c1-2-7-36-23-27-21(26-15-9-12(15)11-3-4-13(24)14(25)8-11)18-22(28-23)31(30-29-18)16-10-17(35-6-5-32)20(34)19(16)33/h3-4,8,12,15-17,19-20,32-34H,2,5-7,9-10H2,1H3,(H,26,27,28)/t12-,15+,16+,17-,19-,20+/m0/s1

Molecular Formula

C23H28F2N6O4S

HBD / HBA

4 / 12

Ligações Rotacionáveis

10

Átomos Pesados

36

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

This antiplatelet medication is used to prevent blood clots in people who have had a heart attack or unstable angina, reducing the risk of future heart attacks and strokes. It works by blocking a receptor on platelets called P2Y12, making platelets less likely to clump together. It is typically taken along with low-dose aspirin and should not be stopped without consulting a doctor.

Yes, Ticagrelor is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL398435. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9871419. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Procura informações acessíveis para o paciente?

Ticagrelor no PillFYI

Estrutura

Dados Rápidos

Fórmula: C23H28F2N6O4S
Sinônimos: 1

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.